Magny les Hameaux, France

Emmanuelle Le Chatelier

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Emmanuelle Le Chatelier: Pioneering Innovations in Microbiota Research

Introduction: Emmanuelle Le Chatelier is a renowned inventor based in Magny les Hameaux, France, recognized for her significant contributions to the field of microbiota and its implications in cancer treatment. With a total of two patents to her name, she is at the forefront of developing innovative methodologies that enhance the efficacy of cancer immunotherapies.

Latest Patents: Emmanuelle's latest patents focus on the use of microbiota composition as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies. Her inventions delve into gut microbiota profiles that associate with patients' responses to treatments involving immune checkpoint blockers (ICB). The patents outline a theranostic method designed to identify which patients would benefit from anti-PD1, anti-PD-L1, or anti-PD-L2 therapies. For those classified as poor responders due to dysbiosis, Emmanuelle's approach includes pre-treatment options such as fecal microbiota transplantation (FMT) and/or the use of immunogenic probiotics to enhance treatment outcomes. Her research highlights specific commensal species that can differentiate between good responders and those who may experience disease progression.

Career Highlights: Throughout her career, Emmanuelle Le Chatelier has worked at prestigious institutions, including the Gustave Roussy Institute and the National Institute of Health and Medical Research (INSERM). Her research has consistently focused on microbiota and its critical role in health and disease, particularly in oncology.

Collaborations: Emmanuelle has collaborated with notable colleagues in the field, including Laurence Zitvogel and Bertrand Routy. These collaborations have bolstered her work and contributed to advancing understanding of the relationship between microbiota and cancer therapies.

Conclusion: Emmanuelle Le Chatelier’s innovative work exemplifies the potential of microbiota research in personalized cancer treatment. Through her patents, she continues to pave the way for new therapeutic strategies that harness the power of gut microbiomes, ultimately aiming to improve patient outcomes in oncology. Her contributions highlight the intersection of innovative research and practical applications in medicine, showcasing the importance of microbiota in enhancing the efficacy of cancer treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…